Quest Diagnostics announced the results of its 2026 Annual Meeting, where stockholders elected all director nominees and approved executive compensation and the appointment of PricewaterhouseCoopers. A stockholder proposal to mandate an independent board chairman was defeated, receiving 23,999,636 votes in favor and 69,792,819 votes against.
